JP2010513569A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010513569A5 JP2010513569A5 JP2009543177A JP2009543177A JP2010513569A5 JP 2010513569 A5 JP2010513569 A5 JP 2010513569A5 JP 2009543177 A JP2009543177 A JP 2009543177A JP 2009543177 A JP2009543177 A JP 2009543177A JP 2010513569 A5 JP2010513569 A5 JP 2010513569A5
- Authority
- JP
- Japan
- Prior art keywords
- alcohol
- drug
- antagonists
- item
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 107
- 239000003814 drug Substances 0.000 claims description 61
- 229940079593 drug Drugs 0.000 claims description 58
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 52
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 50
- 230000004048 modification Effects 0.000 claims description 30
- 238000012986 modification Methods 0.000 claims description 30
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims description 29
- 229960004394 topiramate Drugs 0.000 claims description 29
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 claims description 28
- 229960005343 ondansetron Drugs 0.000 claims description 28
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 25
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 25
- 238000011282 treatment Methods 0.000 claims description 25
- 239000003420 antiserotonin agent Substances 0.000 claims description 24
- 208000028505 alcohol-related disease Diseases 0.000 claims description 23
- 239000005557 antagonist Substances 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 208000007848 Alcoholism Diseases 0.000 claims description 16
- 208000035475 disorder Diseases 0.000 claims description 15
- 229940122459 Glutamate antagonist Drugs 0.000 claims description 14
- 201000007930 alcohol dependence Diseases 0.000 claims description 14
- 239000003112 inhibitor Substances 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 229940121356 serotonin receptor antagonist Drugs 0.000 claims description 14
- 239000000952 serotonin receptor agonist Substances 0.000 claims description 13
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 claims description 12
- 108091006146 Channels Proteins 0.000 claims description 12
- 239000003210 dopamine receptor blocking agent Substances 0.000 claims description 12
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims description 12
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 12
- 229940125681 anticonvulsant agent Drugs 0.000 claims description 11
- 239000001961 anticonvulsive agent Substances 0.000 claims description 11
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 11
- 229940123605 Dopamine release inhibitor Drugs 0.000 claims description 10
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims description 10
- 239000003194 amino acid receptor blocking agent Substances 0.000 claims description 10
- 239000000928 excitatory amino acid agonist Substances 0.000 claims description 10
- 239000003148 4 aminobutyric acid receptor blocking agent Substances 0.000 claims description 9
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims description 9
- 229960003086 naltrexone Drugs 0.000 claims description 9
- 208000029650 alcohol withdrawal Diseases 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000003401 opiate antagonist Substances 0.000 claims description 8
- 239000000556 agonist Substances 0.000 claims description 6
- 239000002220 antihypertensive agent Substances 0.000 claims description 6
- 239000003246 corticosteroid Substances 0.000 claims description 6
- -1 neurokinins Substances 0.000 claims description 6
- 230000004580 weight loss Effects 0.000 claims description 6
- 208000008589 Obesity Diseases 0.000 claims description 5
- 239000000883 anti-obesity agent Substances 0.000 claims description 5
- 239000003472 antidiabetic agent Substances 0.000 claims description 5
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 claims description 5
- 239000003524 antilipemic agent Substances 0.000 claims description 5
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 235000020824 obesity Nutrition 0.000 claims description 5
- 230000002085 persistent effect Effects 0.000 claims description 5
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims description 4
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 4
- 229940122697 Glutamine antagonist Drugs 0.000 claims description 4
- 206010033307 Overweight Diseases 0.000 claims description 4
- 230000036528 appetite Effects 0.000 claims description 4
- 235000019789 appetite Nutrition 0.000 claims description 4
- 229940049706 benzodiazepine Drugs 0.000 claims description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 229960002748 norepinephrine Drugs 0.000 claims description 4
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 208000020925 Bipolar disease Diseases 0.000 claims description 3
- 206010012218 Delirium Diseases 0.000 claims description 3
- 206010012225 Delirium tremens Diseases 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 3
- 102000005915 GABA Receptors Human genes 0.000 claims description 3
- 108010005551 GABA Receptors Proteins 0.000 claims description 3
- 208000004547 Hallucinations Diseases 0.000 claims description 3
- 208000019022 Mood disease Diseases 0.000 claims description 3
- 208000006246 alcohol withdrawal delirium Diseases 0.000 claims description 3
- 208000022780 alcohol-induced mental disease Diseases 0.000 claims description 3
- 229940030600 antihypertensive agent Drugs 0.000 claims description 3
- 229960001334 corticosteroids Drugs 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 208000020016 psychiatric disease Diseases 0.000 claims description 3
- 229940044551 receptor antagonist Drugs 0.000 claims description 3
- 239000002464 receptor antagonist Substances 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 239000003488 releasing hormone Substances 0.000 claims description 3
- 208000012201 sexual and gender identity disease Diseases 0.000 claims description 3
- 208000015891 sexual disease Diseases 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims description 2
- 208000000044 Amnesia Diseases 0.000 claims description 2
- 208000031091 Amnestic disease Diseases 0.000 claims description 2
- 208000029197 Amphetamine-Related disease Diseases 0.000 claims description 2
- 208000022497 Cocaine-Related disease Diseases 0.000 claims description 2
- 206010012239 Delusion Diseases 0.000 claims description 2
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 claims description 2
- 208000030814 Eating disease Diseases 0.000 claims description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
- 208000030990 Impulse-control disease Diseases 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- 208000003863 Marijuana Abuse Diseases 0.000 claims description 2
- 208000026251 Opioid-Related disease Diseases 0.000 claims description 2
- 230000006986 amnesia Effects 0.000 claims description 2
- 231100000868 delusion Toxicity 0.000 claims description 2
- 235000014632 disordered eating Nutrition 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims description 2
- 229930195712 glutamate Natural products 0.000 claims description 2
- 239000000380 hallucinogen Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 229960002715 nicotine Drugs 0.000 claims description 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 2
- 238000002203 pretreatment Methods 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 208000019116 sleep disease Diseases 0.000 claims description 2
- 208000020685 sleep-wake disease Diseases 0.000 claims description 2
- 231100000331 toxic Toxicity 0.000 claims description 2
- 230000002588 toxic effect Effects 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 229940082988 antihypertensives serotonin antagonists Drugs 0.000 claims 7
- 239000003887 narcotic antagonist Substances 0.000 claims 5
- 239000003825 glutamate receptor antagonist Substances 0.000 claims 4
- 229940005501 dopaminergic agent Drugs 0.000 claims 3
- 229940125708 antidiabetic agent Drugs 0.000 claims 2
- 229940125710 antiobesity agent Drugs 0.000 claims 2
- 230000004071 biological effect Effects 0.000 claims 2
- 238000013270 controlled release Methods 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 241001514645 Agonis Species 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- 206010033864 Paranoia Diseases 0.000 claims 1
- 208000027099 Paranoid disease Diseases 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 229940009098 aspartate Drugs 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 239000003179 convulsant agent Substances 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims 1
- 230000002688 persistence Effects 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 229940126586 small molecule drug Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 106
- 238000002560 therapeutic procedure Methods 0.000 description 10
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 4
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 4
- 229940127003 anti-diabetic drug Drugs 0.000 description 3
- 229940127088 antihypertensive drug Drugs 0.000 description 3
- 230000001149 cognitive effect Effects 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 230000000147 hypnotic effect Effects 0.000 description 3
- 102000035037 5-HT3 receptors Human genes 0.000 description 2
- 108091005477 5-HT3 receptors Proteins 0.000 description 2
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 2
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 2
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 2
- WUFQLZTXIWKION-UHFFFAOYSA-N Deoxypeganine Chemical compound C1C2=CC=CC=C2N=C2N1CCC2 WUFQLZTXIWKION-UHFFFAOYSA-N 0.000 description 2
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 description 2
- 229960004047 acamprosate Drugs 0.000 description 2
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 description 2
- 238000001467 acupuncture Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 239000002830 appetite depressant Substances 0.000 description 2
- 229960004372 aripiprazole Drugs 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 238000013542 behavioral therapy Methods 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- 230000010485 coping Effects 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 229960002563 disulfiram Drugs 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229960003980 galantamine Drugs 0.000 description 2
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 2
- 238000013160 medical therapy Methods 0.000 description 2
- 229960005297 nalmefene Drugs 0.000 description 2
- 229960004127 naloxone Drugs 0.000 description 2
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 2
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 description 2
- 229960003015 rimonabant Drugs 0.000 description 2
- 229960001534 risperidone Drugs 0.000 description 2
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 2
- 229960002073 sertraline Drugs 0.000 description 2
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 2
- 229960003991 trazodone Drugs 0.000 description 2
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 2
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 208000013200 Stress disease Diseases 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000464 adrenergic agent Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229940083712 aldosterone antagonist Drugs 0.000 description 1
- 239000002170 aldosterone antagonist Substances 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940035678 anti-parkinson drug Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 239000003200 antithyroid agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 229940125690 blood glucose regulator Drugs 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 239000000064 cholinergic agonist Substances 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 239000002475 cognitive enhancer Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- 150000002309 glutamines Chemical class 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000000937 inactivator Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87566806P | 2006-12-19 | 2006-12-19 | |
| US89852807P | 2007-01-31 | 2007-01-31 | |
| US93103107P | 2007-05-21 | 2007-05-21 | |
| PCT/US2007/088100 WO2008077092A2 (en) | 2006-12-19 | 2007-12-19 | Combined effects of topiramate and ondansetron on alcohol consumption |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010513569A JP2010513569A (ja) | 2010-04-30 |
| JP2010513569A5 true JP2010513569A5 (https=) | 2011-02-10 |
Family
ID=39537067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009543177A Pending JP2010513569A (ja) | 2006-12-19 | 2007-12-19 | アルコール摂取に対するトピラメートおよびオンダンセトロンの併用効果 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20100041689A1 (https=) |
| EP (2) | EP2556830A1 (https=) |
| JP (1) | JP2010513569A (https=) |
| AU (1) | AU2007333656A1 (https=) |
| CA (1) | CA2673481A1 (https=) |
| CR (1) | CR10938A (https=) |
| MX (1) | MX2009006672A (https=) |
| WO (1) | WO2008077092A2 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2677205A1 (en) * | 2007-01-31 | 2008-08-07 | University Of Virginia Patent Foundation | Topiramate plus naltrexone for the treatment of addictive disorders |
| WO2009029308A1 (en) * | 2007-08-27 | 2009-03-05 | University Of Virginia Patent Foundation | Medication combinations for the treatment of alcoholism and drug addiction |
| MX2010009509A (es) | 2008-02-28 | 2010-11-30 | Univ Virginia | Gen transportador de serotonina y tratamiento de alcoholismo. |
| US9226918B2 (en) | 2008-12-04 | 2016-01-05 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating or preventing narcotic withdrawal symptoms |
| RU2393868C1 (ru) * | 2009-05-08 | 2010-07-10 | Надежда Дмитриевна Агаркина | Способ лечения алкогольной зависимости |
| MX2012007813A (es) * | 2010-01-07 | 2012-08-01 | Vivus Inc | Tratamiento del sindrome de apnea obstructiva del sueño con una combinacion de un hinibidor de anhidrasa carbonica y un agente activo adicional. |
| EA024450B1 (ru) | 2010-07-02 | 2016-09-30 | Юниверсити Оф Вирджиния Пэтент Фаундейшн | Молекулярно-генетический подход к лечению и диагностике алкогольной и наркотической зависимости |
| US20130072516A1 (en) * | 2011-09-07 | 2013-03-21 | Eagle Advancement Institute Llc | Method of alcohol cessation and treatment |
| EP2751137A4 (en) * | 2011-09-09 | 2015-06-03 | Univ Virginia Patent Found | MOLECULAR GENETIC APPROACH FOR THE TREATMENT AND DIAGNOSIS OF ALCOHOL AND DRUG INDEPENDENCE |
| WO2014152207A1 (en) | 2013-03-15 | 2014-09-25 | Mylan Laboratories, Inc. | Hot melt granulation formulations of poorly water-soluble active agents |
| US9192570B2 (en) | 2013-12-20 | 2015-11-24 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
| CN107406370A (zh) | 2014-12-09 | 2017-11-28 | 以西结·戈兰 | 酒精饮料替代品 |
| DK3230255T3 (da) | 2014-12-09 | 2020-06-22 | Ezekiel Golan | Regulatorer af uhæmmet adfærd |
| US10420756B2 (en) | 2015-03-26 | 2019-09-24 | Sen-Jam Pharmaceutical Llc. | Methods and compositions to inhibit symptoms associated with veisalgia |
| EP3876938A4 (en) | 2018-11-06 | 2022-08-10 | Purdue Pharma L.P. | COMPOSITIONS AND METHODS OF ADMINISTRATION OF OPIOID ANTAGONISTS |
| CN113906518A (zh) * | 2019-05-02 | 2022-01-07 | 闭环医药有限公司 | 用于向患者提供个性化医疗的方法和系统 |
| US20220117916A1 (en) * | 2020-10-19 | 2022-04-21 | SafeRx Pharmaceuticals, LLC | Combination Products to Mitigate the Risk of Non-Benzodiazepine Benzodiazepine Agonist Adverse Reaction and Overdose |
| US12420014B2 (en) | 2023-06-05 | 2025-09-23 | Closed Loop Medicine Ltd. | Dosing of incretin pathway drugs |
| US12597496B2 (en) | 2023-06-05 | 2026-04-07 | Closed Loop Medicine Ltd. | Dosing of incretin pathway drugs |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES413944A1 (es) | 1972-04-20 | 1976-06-01 | Merz & Co | Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5. |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4160452A (en) | 1977-04-07 | 1979-07-10 | Alza Corporation | Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US5550021A (en) * | 1990-02-07 | 1996-08-27 | Board Of Regents, The University Of Texas System | Allelic diagnosis of susceptibility to compulsive disorder |
| DE4010079A1 (de) | 1990-03-29 | 1991-10-02 | Lohmann Therapie Syst Lts | Pharmazeutische formulierung zur behandlung des alkoholismus |
| EP0714663A3 (en) * | 1994-11-28 | 1997-01-15 | Lilly Co Eli | Potentiation of drug responses by serotonin 1A receptor antagonists |
| EP0945133A1 (en) * | 1998-03-26 | 1999-09-29 | Lipha | Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator |
| US6200604B1 (en) | 1998-03-27 | 2001-03-13 | Cima Labs Inc. | Sublingual buccal effervescent |
| US20040167164A1 (en) * | 1998-05-05 | 2004-08-26 | Jose Pozuelo | Compositions and methods for treating particular chemical addictions and mental illnesses |
| US6287765B1 (en) * | 1998-05-20 | 2001-09-11 | Molecular Machines, Inc. | Methods for detecting and identifying single molecules |
| SE9803240D0 (sv) | 1998-09-24 | 1998-09-24 | Diabact Ab | A pharmaceutical composition having a rapid action |
| CN100548290C (zh) * | 1999-02-24 | 2009-10-14 | 辛辛那提大学 | 氨基磺酸酯衍生物用于治疗冲动控制障碍的用途 |
| WO2002026118A2 (en) * | 2000-09-29 | 2002-04-04 | New Health Sciences, Inc. | Systems and methods for assessing vascular effects of a treatment |
| US7122308B2 (en) * | 2001-02-16 | 2006-10-17 | Centre For Addiction And Mental Health | Detection of antidepressant induced mania |
| US7033771B2 (en) * | 2001-05-08 | 2006-04-25 | Takeda Pharmaceutical Company Limited | Use of insulin response modulators in the treatment of diabetes and insulin resistance |
| EP1262196A3 (en) * | 2001-05-23 | 2002-12-18 | Pfizer Products Inc. | Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence |
| RU2004107501A (ru) * | 2001-08-14 | 2005-02-20 | Байотай Терапис Корпорейшн (Fi) | Способ лечения алкоголизма или злоупотребления алкоголем |
| WO2003018843A1 (en) * | 2001-08-21 | 2003-03-06 | Smithkline Beecham Corporation | Gene polymorphisms and response to treatment |
| US20060173064A1 (en) | 2001-08-24 | 2006-08-03 | Lippa Arnold S | (-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders |
| US20030114475A1 (en) * | 2001-10-31 | 2003-06-19 | Addiction Therapies, Inc. | Methods for the treatment of addiction |
| EP1617832B1 (en) | 2003-04-29 | 2008-03-12 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
| GB0316915D0 (en) * | 2003-07-18 | 2003-08-20 | Glaxo Group Ltd | Compounds |
| US7163969B2 (en) * | 2003-10-14 | 2007-01-16 | Stockhausen, Inc. | Superabsorbent polymer aqueous paste and coating |
| US20050245461A1 (en) * | 2004-03-19 | 2005-11-03 | Elliot Ehrich | Methods for treating alcoholism |
| CN2722428Y (zh) | 2004-07-21 | 2005-08-31 | 上海正贝照明电器有限公司 | 镇流器内藏式一体化节能灯 |
| BRPI0616344A2 (pt) * | 2005-09-26 | 2011-06-14 | Avigen Inc | mÉtodo para o tratamento de dependÊncia quÍmica e comportamental |
| US20070292880A1 (en) * | 2006-05-05 | 2007-12-20 | Robert Philibert | Compositions and methods for detecting predisposition to a substance use disorder or to a mental illness or syndrome |
| US20080004260A1 (en) * | 2006-06-29 | 2008-01-03 | Transcept Pharmaceuticals, Inc. | Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions |
| US7645750B2 (en) * | 2006-12-13 | 2010-01-12 | Yung Shin Pharmaceutical Ind. Co., Ltd. | Method of treating symptoms of hormonal variations |
| CA2677205A1 (en) * | 2007-01-31 | 2008-08-07 | University Of Virginia Patent Foundation | Topiramate plus naltrexone for the treatment of addictive disorders |
| US20080228700A1 (en) * | 2007-03-16 | 2008-09-18 | Expanse Networks, Inc. | Attribute Combination Discovery |
| WO2009026381A2 (en) * | 2007-08-21 | 2009-02-26 | University Of Virginia Patent Foundation | Method, computer program product and system for individual assessment of alcohol sensitivity |
| WO2009029308A1 (en) * | 2007-08-27 | 2009-03-05 | University Of Virginia Patent Foundation | Medication combinations for the treatment of alcoholism and drug addiction |
| MX2010009509A (es) * | 2008-02-28 | 2010-11-30 | Univ Virginia | Gen transportador de serotonina y tratamiento de alcoholismo. |
| WO2009134944A2 (en) * | 2008-04-29 | 2009-11-05 | Nodality, Inc. | Methods of determining the health status of an individual |
| EP2425013A1 (en) * | 2009-05-01 | 2012-03-07 | University Of Virginia Patent Foundation | Serotonin transporter gene and treatment of alcoholism |
-
2007
- 2007-12-19 JP JP2009543177A patent/JP2010513569A/ja active Pending
- 2007-12-19 MX MX2009006672A patent/MX2009006672A/es unknown
- 2007-12-19 WO PCT/US2007/088100 patent/WO2008077092A2/en not_active Ceased
- 2007-12-19 EP EP12170027A patent/EP2556830A1/en not_active Withdrawn
- 2007-12-19 US US12/520,095 patent/US20100041689A1/en not_active Abandoned
- 2007-12-19 CA CA002673481A patent/CA2673481A1/en not_active Abandoned
- 2007-12-19 EP EP07869501A patent/EP2124909A4/en not_active Withdrawn
- 2007-12-19 AU AU2007333656A patent/AU2007333656A1/en not_active Abandoned
-
2009
- 2009-07-17 CR CR10938A patent/CR10938A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010513569A5 (https=) | ||
| JP2010537990A5 (https=) | ||
| US20210060009A1 (en) | Novel methods | |
| CN102695502B (zh) | 用于治疗药瘾和改善药瘾相关行为的组合物 | |
| US20240307386A1 (en) | Novel methods | |
| JP2010513569A (ja) | アルコール摂取に対するトピラメートおよびオンダンセトロンの併用効果 | |
| JP2011515076A5 (https=) | ||
| KR20080004580A (ko) | 물질 남용 및 의존의 치료 방법 | |
| Mizobe et al. | α2-Adrenoceptor agonists and anesthesia | |
| O'Rourke et al. | Preoperative management of opioid and nonopioid analgesics: Society for Perioperative Assessment and Quality Improvement (SPAQI) consensus statement | |
| AU2025271432A1 (en) | CGRP antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo | |
| CA2450787C (en) | Active ingredient combination for pharmacological addictive substance or intoxicant therapy | |
| HU226555B1 (en) | Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator | |
| JP2009517393A (ja) | 不安症の治療方法 | |
| CN100386070C (zh) | 包含褪黑激素的药物制剂 | |
| CN101014325A (zh) | 治疗中枢神经系统病症的药物 | |
| Esmat et al. | Comparative study between transdermal nicotine and melatonin patches on postoperative pain relief after laparoscopic cholecystectomy, a double-blind, placebo-controlled trial | |
| Reisner-Keller | Pharmacotherapeutics in the management of orofacial pain | |
| US20060199866A1 (en) | Combination of desoxypeganine and mecamylanine for the treatment of alcohol abuse | |
| US12533325B2 (en) | Composition and method for preventing or treating opioid withdrawal symptoms | |
| UA79752C2 (en) | Active substance combination for medicamentous therapy of nicotine dependency, method of treatment | |
| NZ562585A (en) | Use of slective chloride channel modulators to treat alcohol and/or stimulant substance abuse | |
| EP2186517A1 (en) | Use and methods of use for an antagonist of the serotin3 receptor (5-ht3) and a selective modulator of chloride channels for the treatment of addiction to or dependence on medicines/drugs or nervous system disorders | |
| HK40129313A (zh) | 右美沙芬的经皮递送 | |
| Prescilla | The pharmacology and clinical application of sedatives, analgesics, and adjuncts |